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Edouard Battegay9,10, Jean-Michel Gaspoz11, Eve A Kerr12, Drahomir Aujesky1 and Nicolas Rodondi1*Abstract
Background: Assessment of the proportion of patients with well controlled cardiovascular risk factors
underestimates the proportion of patients receiving high quality of care. Evaluating whether physicians respond
appropriately to poor risk factor control gives a different picture of quality of care. We assessed physician response
to control cardiovascular risk factors, as well as markers of potential overtreatment in Switzerland, a country with
universal healthcare coverage but without systematic quality monitoring, annual report cards on quality of care or
financial incentives to improve quality.
Methods: We performed a retrospective cohort study of 1002 randomly selected patients aged 50–80 years from
four university primary care settings in Switzerland. For hypertension, dyslipidemia and diabetes mellitus, we first
measured proportions in control, then assessed therapy modifications among those in poor control. “Appropriate
clinical action” was defined as a therapy modification or return to control without therapy modification within
12 months among patients with baseline poor control. Potential overtreatment of these conditions was defined as
intensive treatment among low-risk patients with optimal target values.
Results: 20% of patients with hypertension, 41% with dyslipidemia and 36% with diabetes mellitus were in control
at baseline. When appropriate clinical action in response to poor control was integrated into measuring quality of
care, 52 to 55% had appropriate quality of care. Over 12 months, therapy of 61% of patients with baseline poor
control was modified for hypertension, 33% for dyslipidemia, and 85% for diabetes mellitus. Increases in number of
drug classes (28-51%) and in drug doses (10-61%) were the most common therapy modifications. Patients with
target organ damage and higher baseline values were more likely to have appropriate clinical action. We found low
rates of potential overtreatment with 2% for hypertension, 3% for diabetes mellitus and 3-6% for dyslipidemia.
Conclusions: In primary care, evaluating whether physicians respond appropriately to poor risk factor control, in
addition to assessing proportions in control, provide a broader view of the quality of care than relying solely on
measures of proportions in control. Such measures could be more clinically relevant and acceptable to physicians
than simply reporting levels of control.
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Although a broad armamentarium of pharmacothera-
peutic interventions and recommendations are available,
cardiovascular risk factors are often suboptimally con-
trolled. Clinical inertia in the form of insufficient treat-
ment intensification in the face of poor disease control
has been suggested to be a major cause of failure to re-
spond to abnormal measurements [1,2]. While quality of
care measures should ideally reflect whether physicians
and systems deliver appropriate clinical action, most
current measures focus on achievement of a target ra-
ther than changes in treatment [3].
We have previously shown the feasibility of measuring
physician response to poor risk factor control in the US
using electronic treatment records as an additional “tightly
linked” clinical action measure of quality [4,5]. Provider
responses to poorly controlled risk factor levels such as in-
tensification of pharmacotherapy are tightly linked clinical
action measures, which are clinically relevant indicators
for quality of care directly linked to improved patient out-
comes, further improving quality assessment and reducing
risks of overtreatment [3,4,6]. The primary goal of new
action measures is the improvement of quality of care.
Focusing on accountability measures might corrupt the
process of monitoring quality of care [7].
Recently, new measures have also been developed for po-
tential overtreatment of cardiovascular risk factors, such as
hypertension and diabetes mellitus [3,8]. However, limited
data exist about physician response to poor risk factor con-
trol and markers of overtreatment in settings without
systematic quality monitoring. In Switzerland, systematic
quality monitoring and annual report cards on quality of
care [9], and financial incentives to improve quality, are not
implemented. Among other differences from the US, all
patients have universal healthcare coverage in Switzerland.
In the present study, we assessed physician response
to control of hypertension, dyslipidemia, and diabetes
mellitus, as well as markers of potential overtreatment,
among a random sample of 1002 patients aged 50–80
years followed for two years in four Swiss University pri-
mary care settings.
Methods
Study participants
We abstracted medical charts from 1002 randomly se-
lected patients from Swiss university primary care settings
in Basel, Geneva, Lausanne and Zürich to establish a retro-
spective cohort study over 2 years, as described previously
in detail [10]. The Institutional Review Boards at each site
approved the study. This study was approved by the Ethics
Committee of Zürich, the Human Research Ethics Com-
mittee of Geneva, the Human Research Ethics Committee
of Vaud, and the Ethics Committee of Basel, at the sites of
Zürich, Geneva, Lausanne, and Basel, respectively. Therandom sample was drawn from electronic administrative
data of all patients aged 50 to 80 years followed in 2005–
2006. We limited our sample to this age group to have a
high enough prevalence of cardiovascular risk factors. Pa-
tients were followed by residents in general internal medi-
cine at the end of their postgraduate training who were
supervised by university attendings, or were seen directly
by university attendings (10%). Patients who were followed
for less than one year, in a specialized clinic only or who
had no outpatient visit to a primary care physician were
excluded. Nine medical students were centrally trained at
one site (Lausanne) for data abstraction from medical
charts in each Swiss university primary care setting, and
then entered data using EpiData software (version 3.1, Epi-
Data Association, Denmark). We used the same criteria for
the identification of patients with hypertension, dyslipid-
emia, diabetes mellitus as previously published (Additional
file 1: Table S1) [5].
Diagnostic criteria for “Appropriate Clinical Action”
Among patients with poorly controlled hypertension, dys-
lipidemia, or diabetes mellitus during the study period, we
assessed any therapy modification response to one or
more poorly controlled conditions [5]. Patients with near
control of risk factors were not analyzed for therapy modi-
fications because of the appropriateness of lifestyle modifi-
cations for near control of these conditions. Patients with
diabetes already treated with insulin therapy were not in-
cluded into the analysis of therapy modifications, because
day-to-day adjustments in insulin dosage could not be re-
liably identified.
We defined pharmacotherapeutic intervention as an in-
crease in the number of different drug classes, an increase
in the dosage of one or more drugs, or a switch to another
drug class. We defined “appropriate clinical action” as any
of these pharmacotherapeutic interventions or return to
control without therapy modification within 12 months as
physicians may sometimes opt for non-pharmacological
recommendations [5]. Responses were also examined
within six months. Other possibilities were considered “in-
appropriate clinical action” as no return to control, return
to “near control”, or no further measurements without
any pharmacotherapeutic intervention within 12 months.
In terms of quality of care, we compared the differences
between simply measuring proportions of patients with
controlled risk factors (markers in control) and adding ap-
propriate clinical action for those with poor risk factor
control (action measure).
Drugs were grouped into drug classes, with seven antihy-
pertensive classes (thiazides diuretics, other diuretics, beta-
blockers, calcium-channel blockers, angiotensin-converting
enzyme inhibitors, angiotensin-receptor blockers, other
antihypertensives), five lipid-lowering classes (statins,
fibric acid derivatives, niacin, bile acid resins, other
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lin, sulfonylureas, metformin, thiazolidinediones, other
diabetes-related agents). Daily dosages were recorded ex-
cept for insulin whose day-to-day adjustments could not
be reliably identified in this retrospective review of med-
ical charts.
Comorbidities
We analyzed the associations between various patient fac-
tors, such as co-occurrence of several conditions or target
organ disease and “appropriate clinical action” for poorly
controlled conditions. Target organ disease is based on the
definitions of the Joint National Committee 7th report
guidelines [11]: any previous diagnosis of hypertensive
heart disease, congestive heart failure, cerebrovascular or
peripheral arterial disease, and nephropathy. Based on a
previous published study [12], another predictor variable
was the number of comorbidities. Categories of cardiovas-
cular risk included the history of coronary artery disease
(CAD), other target organ disease or no history of either
condition. Previous CAD was defined as any diagnosis
of myocardial infarction, angina pectoris, atherosclerotic
heart disease or coronary revascularization [5].
Markers of potential overtreatment
Recently, criteria for potential overtreatment of hyper-
tension among patients with diabetes mellitus have been
developed [3]. Based on this study and on current guide-
lines at the time of the patient care [11,13], we defined
potential overtreatment of hypertension among diabetic
patients if both low systolic (<130 mmHg) and low dia-
stolic (<65 mmHg) values, and receiving three or more
antihypertensive drugs applied to diabetics and to the
overall sample. We defined potential overtreatment of
dyslipidemia as having low LDL cholesterol (<2.6 mmol/
L or <100 mg/dL) and a high daily dose of statin (atorva-
statin ≥40 mg, rosuvastatin ≥10 mg, simvastatin ≥40 mg)
for individuals without a diagnosis of cardiovascular dis-
ease (primary prevention) [14]. We developed new cri-
teria for potential overtreatment of diabetes mellitus
based on the new ADA guidelines which state that less
stringent glycosylated haemoglobin (HbA1c) goals are
possibly appropriate for patients with limited life expect-
ancy, extensive comorbid conditions13, and supported by
a commentary by Pogach and Aron [8]. Potential over-
treatment of patients with diabetes was defined as pa-
tients with a low HbA1c <7.0%, on treatment with two
or more glucose-lowering agents, when the patient had
multi-morbidity (defined as two or more diseases, ex-
cluding cardiovascular risk factors) [15,16] or a short life
expectancy (defined as a terminal illness, such as cancer).
We did not have any longitudinal data on therapy intensi-
fication among patients with controlled risk factors, as
these data were not collected.Statistical analysis
For patients with poorly controlled hypertension, dyslipid-
emia and diabetes mellitus, we examined percentages of
pharmacotherapeutic interventions or return to normal
levels, as described above. We examined different factors
associated with “appropriate clinical action” at six and
twelve months using multivariable logistic regression. We
used mixed-effects logistic regression (Stata version 12.0,
Stata Corp., College Station, TX) to account for clustering
by the four sites as a fixed factor and physicians as random
factor [17].Results
Population characteristics and degree of control
Baseline demographic characteristics and comorbid condi-
tions are described in Table 1. Among the 1002 patients at
baseline, 753 had hypertension (20% in control and 52%
poorly controlled), 644 had dyslipidemia (41% in control,
36% poorly controlled), and 293 had diabetes (36% in con-
trol, 20% poorly controlled) (Figure 1). When appropriate
clinical action in response to poor control over a 12 month
period was integrated into measuring quality of care, the
proportion of patients receiving appropriate/high quality
of care increased to 52% of patients with hypertension
(391 of 753 patients), 55% of patients with dyslipidemia
(351 of 644) and 53% of patients with diabetes mellitus
(155 of 293 patients) (Figure 1). The highest number of
condition-specific medications was given to patients with
poorly controlled hypertension, with 30% receiving three
or more anti-hypertensive drugs at baseline. More than
60% of patients with poorly controlled hypertension were
on three or more medications at baseline. Patients with
poorly controlled dyslipidemia received the lowest number
of condition-specific drugs at baseline and 71% were un-
treated at baseline. One to two thirds of patients with one
poorly controlled condition had also the other two condi-
tions (Table 2).Therapy modifications during 6-month and 12-month
periods
Within six months, 49% of patients received therapy
modification for poorly controlled blood pressure, 24% for
poorly controlled LDL cholesterol level, and 75% for
poorly controlled HbA1c (Table 3). In most patients ther-
apy was modified by adding another drug class (19-44%)
or by increasing the dosage (7-53%). Within a longer ob-
servation period of 12 months, patients with therapy mod-
ifications slightly increased to 61% for poorly controlled
blood pressure, 33% for poorly controlled LDL-cholesterol
level, and 85% for poorly controlled HbA1c. Although the
number of patients with therapy modifications rose be-
tween 6 and 12 months, a majority of patients had drug
modifications within the first six months. Only a small
Table 1 Baseline characteristics of patients with poorly controlled hypertension, dyslipidemia, and diabetes mellitus
Poorly controlled
Hypertension (n = 391)
Poorly controlled
Dyslipidemia (n = 231)
Poorly controlled diabetes
Mellitus (n = 59)
Demographic
Age, years Mean, (SD) 64.5 (8.1) 62.9 (7.7) 62.8 (8.6)
n % n % n %
Age
< 65 years 193 49 130 56 32 54
≥ 65 years 198 51 101 44 27 46
Sex
Female 159 41 99 43 22 37
Baseline medications
Medication for each condition
0 medications 67 17 165 71 15 25
1 medications 92 24 64 28 18 31
2 medications 115 29 2 1 25 42
3 medications 74 19 0 0 1 2
≥4 medications 43 11 0 0 0 0
Medication for others of the 3 conditions
0 medications 109 28 60 26 9 15
1 medications 98 25 37 16 14 24
2 medications 85 22 52 23 10 17
3 medications 46 12 30 13 13 22
≥4 medications 53 14 52 23 13 22
All medications
0 medications 17 4 22 10 3 5
1 medications 42 11 34 15 6 10
2 medications 52 13 36 16 3 5
3 medications 57 15 42 18 12 20
≥4 medications 223 57 97 42 35 59
Citizenship
Switzerland 171 44 97 42 22 37
Europe/USA 80 20 48 21 10 17
Eastern Europe 83 21 46 20 19 32
Africa 26 7 18 8 5 8
Latin America 15 4 9 4 2 3
Asia/Middle-East 14 4 13 6 1 2
Civil status
Single 51 13 34 15 3 5
Divorced/separated 87 22 63 27 17 29
Widowed 46 12 22 10 6 10
Married 203 52 111 48 33 56
Occupation
Social aid 46 12 25 11 7 12
Unemployed 40 10 20 9 8 14
Employed 92 24 73 32 10 17
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Table 1 Baseline characteristics of patients with poorly controlled hypertension, dyslipidemia, and diabetes mellitus
(Continued)
Retired 159 41 86 37 26 44
At home 45 12 25 11 7 12
Other 2 1 0 0 1 2
Missing data on citizenship for 2 patients with poorly controlled hypertension, on civil status for 4 patients with poorly controlled hypertension and 1
patient with poorly controlled dyslipidemia, on occupation for 7 patients with poorly controlled hypertension, for 2 with poorly controlled
dyslipidemia, respectively.
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12 months without any therapy modifications.
About one third of hypertensive patients with inappro-
priate clinical action remained in poor control without
therapy modification. In contrast, more than half of the
patients receiving inappropriate clinical action for poorly
controlled dyslipidemia had no further LDL-cholesterol
measurement within 6 or 12 months. In patients with
poorly controlled diabetes mellitus and inappropriate
clinical action about 70% were already receiving one or
two oral antidiabetics (77% after six months, 67% after
12 months). In contrast, among patients with poorly
controlled dyslipidemia and inappropriate clinical action
about 70% were not on any single lipid-lowering medica-
tion at baseline.
Multivariable analysis of factors associated with
appropriate clinical action
At 12 months, previous target organ disease and CAD
were independently associated with appropriate clinical0%
10%
20%
30%
40%
50%
60%
Hypertension Dyslipidemia
Appropriate Quality of
Figure 1 Quality of care measurements. Comparison of appropriate qua
control) and appropriate clinical action for poor risk factor control including
factors in control: hypertension n = 151/753 (20%), dyslipidemia 264/644 (4
within 12 months: hypertension 240/753 (32%), dyslipidemia 87/644 (14%),action in response to poor control of dyslipidemia
(Table 4). Higher baseline levels of systolic and diastolic
blood pressure and LDL cholesterol levels were associated
with a higher proportion of appropriate clinical action for
poorly controlled hypertension and dyslipidemia. Patient
gender or age did not influence appropriate clinical action.
Hypertensive patients with CAD or target organ damage
were not more likely to receive appropriate clinical action
in response to elevated blood pressure, than those without
these conditions using multivariable analyses.Potential overtreatment of hypertension, dyslipidemia
and diabetes mellitus
Five out of 256 (2%) diabetic patients with hypertension
met the criteria for overtreatment. Overall, we found 2% of
patients (15/753) to be potentially overtreated for hyperten-
sion, 3% (8/293) for diabetes mellitus, and 3% for dyslipid-
emia (19/644) whereas 6% of patients with diabetes had
potential overtreatment for dyslipidemia (13/236).Diabetes
 Care
Appropriate Clinical Action
In Control
lity of care by simple measuring proportions in control (markers in
physicians’ response (action measure). Patients with baseline risk
1%), diabetes 105/293 (36%). Patients with appropriate clinical action
diabetes 50/293 (17%).
Table 2 Comorbid conditions of the patients with poorly controlled conditions
Co-Conditions and Co-Morbidities
Hypertension poor control
(n = 391)
Dyslipidemia poor control
(n = 231)
Diabetes mellitus poor control
(n = 59)
n % n % n %
Conditions
all three conditions 141 36 60 26 41 69
+ hypertension 187 81 51 86
+ dyslipidemia 294 75 48 81
+ diabetes mellitus 169 43 70 30
Comorbidities
Cerebrovascular Disease (TIA, CVA) 56 14 20 9 6 10
Coronary Artery Disease 75 19 37 16 9 15
Congestive Heart Failure 28 7 11 5 3 5
End Stage Renal Disease 2 1 1 0 0 0
Dementia 9 2 2 1 1 2
COPD 50 13 28 12 10 17
Asthma 16 4 6 3 3 5
Gastric Ulcer 13 3 12 5 5 8
Breast Cancer 6 2 4 2 0 0
Colorectal Cancer 8 2 0 0 1 2
Prostate Cancer 16 4 8 3 2 3
Depression 68 17 46 20 12 20
Number of Comorbidities
Mean, (SD) 2.3 (1.0) 1.9 (1.1) 2.7 (1.0)
Distribution
0 0 0 17 7 0 0
1 87 22 72 31 3 5
2 158 40 81 35 25 42
>2 146 37 61 26 31 53
COPD chronic obstructive pulmonary disease.
Weiler et al. BMC Health Services Research 2014, 14:306 Page 6 of 10
http://www.biomedcentral.com/1472-6963/14/306Discussion
In Switzerland, a country without systematic quality moni-
toring, we found that measuring proportions in control
without evaluating whether physicians respond appropri-
ately to poor risk factor control largely underestimated
quality of care. When appropriate clinical action in re-
sponse to poor control over a 12 month period was inte-
grated into measuring quality of care compared to the
measurement of proportions of patients with controlled
risk factors, proportions with appropriate quality of care
increased for hypertension (20% vs. 52%), for dyslipidemia
(41% vs. 55%), and for diabetes mellitus (36% vs. 53%).
Suboptimal care for poorly controlled cardiovascular
risk factors was provided to 15% to 62% of patients at
12 months in our study. Failure to respond to poorly con-
trolled measurements is a barrier to good clinical and ap-
propriate clinical action of cardiovascular risk factors [1].
Guidelines are frequently changing. For example, recentevidence suggests that treatment with moderate dose sta-
tins is more important than achieving target values for
LDL [14]. However, at baseline over 35% of patients at high
risk of cardiovascular events with an LDL >2.6 mmol/L
were not treated with statins in our study. Other reasons
for inappropriate clinical action might be the patients’ lack
of adherence to pharmacological therapy, missed appoint-
ments, missed laboratory tests or the recommendation for
lifestyle modifications [18], which could not directly be
identified in our data. However, return to control without
any treatment, possibly due to lifestyle modifications, was
counted as appropriate clinical action in our study.
To our knowledge, this is the first study in a country
without systematic quality monitoring, to document ap-
propriate physician response to poor control of cardiovas-
cular risk factors and potential overtreatment. Systematic
quality monitoring is widely used in the US and in the UK
[16]. It has been shown that higher quality of care might
Table 3 Patients with poorly controlled hypertension, dyslipidemia, or diabetes mellitus, who had subsequent therapy
modifications within a 6-months or 12 months-period
Patients with poorly controlled
hypertension
Patients with poorly controlled
dyslipidemia
Patients with poorly controlled
diabetes mellitus
6 Months 12 Months 6 Months 12 Months 6 Months 12 Months
n % n % n % n % n % n %
Appropriate clinical action 211 54.0 240 61.4 67 29.0 87 37.7 46 78.0 50 84.7
Any therapy modification 193 49.4 238 60.9 55 23.8 77 33.3 44 74.6 50 84.7
Increase class 121 30.9 153 39.1 43 18.6 64 27.7 26 44.1 30 50.8
Increase dose 103 26.3 135 34.5 15 6.5 23 10.0 31 52.5 36 61.0
Switch class† 30 7.7 49 12.5 0 0.0 2 0.9 6 10.2 10 16.9
Several modifications 55 14.1 88 22.5 3 1.3 11 4.8 19 32.2 26 44.1
Return to control WO modification‡ 18 4.6 2 0.5 12 5.2 10 4.3 2 3.4 0 0.0
Inappropriate clinical action 180 46.0 151 38.6 164 71.0 144 62.3 13 22.0 9 15.3
No modification, return to near control‡ 25 6.4 9 2.3 38 16.5 27 11.7 1 1.7 3 5.1
No modification, no return‡ 120 30.7 134 34.3 40 17.3 40 17.3 7 11.9 2 3.4
No measurement, no modification 35 9.0 8 2.0 86 37.2 77 33.3 5 8.5 4 6.8
LDL = low-density lipoprotein. †A switch to different drug class was counted when a new class of medication for the condition was added, but the total number of
drug classes remained the same. ‡Categories of control with levels of control, near and poor control for hypertension, dyslipidemia and diabetes mellitus are
based on N. Rodondi et al. [5]. This category includes patients without visit or measurements.
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are established [19]. Other factors influencing physicians’
prescription behaviour are likely to be similar to those in
the US setting, such as adherence to the same US treat-
ment guidelines (or slight adaptation of them) and potential
industrial influence, with several industrial headquarters in
Switzerland. As most physicians in our study had a fixed
salary, it is unlikely that financial incentives played a signifi-
cant role in our results. Previous studies on quality of care
based on therapy modifications in response to cardiovascu-
lar risk factors were primarily performed in countries with
quality monitoring such as the US [5,7,20-22]. In a previous
study from the US, the rates of therapy modifications for
poorly controlled blood pressure were comparable to our
study, slightly lower for poorly controlled HbA1c, and
higher for poorly controlled LDL cholesterol levels [7]. In
contrast, recent studies from the US Department of
Veterans Affairs showed higher levels of therapy modifi-
cation and treatment, along with higher levels of poten-
tial overtreatment. In these studies, Kerr and colleagues
showed that high rates of performance on measures that
assessed attainment of risk factor thresholds may be
associated with overtreatment [3,14], while our study
found high levels of therapy modification with low rates
of overtreatment.
In the US studies previously reported, patients with 1
or more of the 3 conditions, those with higher baseline
values of cardiovascular risk factors, target organ dam-
age, younger age or more “routine visits” were more
likely to receive appropriate clinical action for all of the
three risk factors [5,23-25].Higher rates of appropriate clinical action for poorly
controlled hypertension and dyslipidemia were found
among patients with higher baseline levels of blood pres-
sure and LDL cholesterol levels, respectively. Potential
overtreatment of these conditions seemed to be low for
patients with already well controlled risk factors.
Results from our study show, that high rates of appro-
priate clinical action and low proportions of overtreatment
may also be achieved in a country without systematic
quality monitoring. In Switzerland all patients have uni-
versal healthcare coverage, including adults with low in-
come who receive social aid to cover healthcare costs,
regardless of their age or whether they work. Meeting clin-
ical action measures rather than the treat-to-target ap-
proach of surrogate markers is now more and more
recommended to improve appropriateness of care [3,8,14].
These measures include clinical processes that are associ-
ated with important outcomes. Simply assessing measures
of cardiovascular risk factor control without action mea-
sures largely minimizes the quality of care provided by
physicians and other healthcare providers. We suggest that
assessment of quality of care can be improved by includ-
ing measures of therapy intensification and physician ac-
tion in the face of uncontrolled values.
Overtreatment might reflect overaggressive and poten-
tially dangerous lowering of markers among low-risk pa-
tients, and the use of expensive condition-specific drugs
with unproven mortality and/or morbidity benefits [26].
Overtreatment of cardiovascular risk factors seemed to be
low in the present cohort. In a recent study, Kerr et al.
found 8% of potential overtreatment for hypertension
Table 4 Multivariable analysis of factors associated with “Appropriate Clinical Action” in response to poorly controlled
hypertension, dyslipidemia, and diabetes mellitus at 12 months
Poorly controlled hypertension
(n = 391)
Poorly controlled dyslipidemia
(n = 231)
Poorly controlled diabetes
Mellitus (n = 59)
Proportion OR 95% CI Proportion OR 95% CI Proportion OR 95% CI
(%) (%) (%)
Age
<65 years 59.0 35.8 98.2
≥65 years 66.6 1.38 (0.86-2.22) 31.9 0.84 (0.41-1.71) 97.9 0.86 (0.14-5.23)
Sex
Female 64.5 40.5 98.5
Male 61.8 0.89 (0.56-1.43) 29.7 0.62 (0.29-1.30) 97.6 0.60 (0.09-3.99)
Co-occurrence of other conditions
no co-occurrence of HT, DL, DM 62.0 42.0 NA
HT and DL 67.1 1.25 (0.64-2.41) 30.8 0.62 (0.19-1.98)
HT and DM 62.8 1.03 (0.35-3.06) 76.3 ref
DL and DM 9.4 0.14 (0.01-1.43) 100.0 NA
All 3 conditions 58.7 0.87 (0.41-1.86) 43.6 1.07 (0.23-5.00) 90.1 2.81 (0.27-29.11)
Number of other conditions
increase 1 co-morbidity 1.23 (0.93-1.63) 0.92 (0.57-1.49) 0.63 (0.19-2.09)
Risk status
No target organ disease 61.4 17.9 NA
Target organ disease (except CAD) 65.4 1.19 (0.56-2.52) 49.0 4.41 (1.59-12.19)** 97.6 ref
CAD 56.0 0.80 (0.31-2.07) 51.0 4.78 (1.27-18.02)* 99.3 3.27 (0.12-87.75)
Baseline level of each condition
Systolic BP
140-159 mmHg 59.9
160-179 mmHg 62.6 1.12 (0.67-1.88)
≥180 mmHg 93.0 8.86 (1.06-73.98)*
Diastolic BP
90-99 mmHg 59.9
100-109 mmHg 73.7 1.88 (0.87-4.08)
≥110 mmHg 91.0 6.78 (0.71-65.14)
LDL cholesterol level
3.4-4.1 mmol/L (130–159 mg/dL) 22.5
4.2-4.9 mmol/L (160–189 mg/dL) 44.6 2.77 (1.15-6.68)*
≥5.0 mmol/L (≥190 mg/dL) 54.2 4.08 (1.32-12.62)*
Haemoglobin A1c
8.0-8.9% 98.1
9.0-9.9% 99.0 2.75 (0.12-31.21)
≥10.0% 96.0 0.45 (0.07-3.07)
Hierarchical logistic regression with adjustment for all the covariates in the table. Patient factors associated with “appropriate clinical action” vs. “inappropriate
clinical action” at 12 months were assessed in these multivariable models. “Appropriate clinical action” was defined as therapy modifications or return to control
without therapy modification. BP = blood pressure; CAD = coronary artery disease; LDL = low-density lipoprotein; HT = hypertension; DL = dyslipidemia; DM = diabetes
mellitus. OR = odds ratio; 95% CI = 95% confidence interval; NA = not available. Odds Ratios are related to the first class shown for each category. Due to low number of
patients with poorly controlled diabetes mellitus some calculations for proportions, odds ratios and 95% confidence interval are not feasible. Ref = reference category in
diabetes mellitus due to low number of patients. *P < 0.05 compared to reference group; **P < 0.01 compared to reference group.
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blood pressure (<130/65 mmHg) [3]. In the present study,
we extended this analysis to hypertensive patients without
diabetes mellitus, and found the same rate of potential
overtreatment of hypertension in the two groups (2%).
Overtreatment of hyperlipidemia has been shown to be
common in the outpatient setting (8-13%) [14,27,28].
Our study has several limitations. First, we could not
identify the many potential causes of nonresponse to poor
control and the reasons for intensified therapy in the face
of low surrogate markers. Second, for overtreatment,
widely used guidelines at the time of data collection, such
as the American Diabetes Association (ADA) or Seventh
Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pres-
sure (JNC 7) [11,13] do not specify lower thresholds of
blood pressure or HbA1c goals. Recent large studies have
not shown significant mortality benefit among patients in-
tensively treated for hypertension and diabetes mellitus
[29-31], while one group reported increased mortality
after intensive glucose lowering therapy in type 2 diabetes
[32]. The ADA now mentions that less stringent treatment
goals (HbA1c > 7%) may be appropriate for adults with
limited life expectancy or co-morbidities [13]. The defini-
tions of overtreatment are recent and no consensus on
these new markers have been reached. To define over-
treatment, we used recent publications and widely used
guidelines. Third, data from the present cohort were ob-
tained in university settings and results might differ for
general practitioners in the community. Care provided by
university attendings and residents might be more guide-
line driven, leading to increased percentage of appropriate
clinical action, but also potential overtreatment. Fourth,
for diabetes mellitus, our measure of physician response
was not applicable to patients with insulin treatment as
data on day-to-day adjustments of dosages were not reli-
ably recorded. While we have previously shown that treat-
ment intensification was tightly linked to improved risk
factor control [4], our study did not allow conclusions on
morbidity or mortality of cardiovascular risk factors with
regard to quality of care including action measures. Lastly,
we could not assess the predictors of each component of
appropriate clinical action, because the sample size was
too small for multivariate analyses.
Conclusions
In summary, evaluating whether physicians respond ap-
propriately to poor risk factor control, in addition to pro-
portions of patients with controlled risk factors, might
provide a more clinically relevant index of quality of care.
This might result in a broader view of the quality of care
than relying solely on measures of proportions in control.
Such measures could be more clinically relevant and ac-
ceptable to physicians than simply reporting levels ofcontrol. Overall, rates of overtreatment for cardiovascular
risk factors were low, ranging from 2% to 6%. Sophisti-
cated quality measures including action measures may
provide a better picture of the quality of care than relying
only on measures of proportions in control.
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